Merrick & Company

About Merrick & Company

Merrick & Company sits in Other / Uncategorized, a segment Bracken sees as structurally important to the radiopharma value chain.

Longer summary placeholder. Replace once Bracken finalizes the exhibitor profile copy.

What we're seeing

• Reuters Health · 2026-09-04
  Merrick Company expands cyclotron capacity to meet Lu-177 demand
  Coverage notes the company's growing footprint in the radioligand therapy space.
• Endpoints News · 2026-02-11
  Merrick Company announces Phase II readout for lead theranostic candidate
  Industry observers expect more activity of this kind in the run-up to SNMMI 2026.
• FierceBiotech · 2026-11-18
  Merrick Company appoints new Chief Medical Officer ahead of pivotal trial
  The announcement comes amid tightening Mo-99 and Lu-177 supply.
• BioPharma Reporter · 2026-08-25
  Merrick Company signs supply agreement to support late-stage trials
  Details remain limited but analysts read the move as a positioning play ahead of pivotal data.
• Imaging Wire · 2026-05-04
  Merrick Company closes Series C round to scale radiopharma manufacturing
  Industry observers expect more activity of this kind in the run-up to SNMMI 2026.

Mocked while we wire the Exa integration. Headlines are illustrative.

What we expect to see at the booth

Booth talking points, demos, and announcements to watch for. Bracken analyst note coming.